Universitaet Leipzig
- Address
- lock Available on a paid plan
Skin and Connective Tissue Diseases
At Universitaet Leipzig, clinical research in Dermatology, Venereology, and Allergology is centered on skin and connective tissue diseases, with a strong focus on ulcerative pyoderma gangrenosum. The trials are designed to assess whether new treatment approaches can improve outcomes for patients living with this rare and difficult-to-treat inflammatory condition.
- Studies focused on ulcerative pyoderma gangrenosum and related inflammatory skin disorders
- Research evaluating the effectiveness and safety of emerging therapies
- Clinical work aimed at improving treatment options for complex dermatologic disease
With 6 clinical trials and 106 investigators contributing to the program, the site supports focused research on better therapies for this rare skin disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 24 therapeutic areas and 15 of 607 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 579 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 109 by active trials.
- 1AstraZeneca AB13active
lock +108 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB24trials
lock +68 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitaet Leipzig
lock Showing 1 of 433 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21196) A multicenter, prospective, open-label study to evaluate the pharmacokinetics and safety of gadoquatrane in pediatric participants (from birth to <18 years) undergoing contrast-enhanced magnetic resonance imaging (CE-MRI) | Bayer AG | Phase III | Not Yet Recruiting | Oct 2023 | Nov 2024 |
IMP list
lock Showing 1 of 607 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 35 | Unknown | 2015-07-16 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.